Related Experiment Videos
Olfactory neuroblastoma. Response to combination chemotherapy
Archives of Otolaryngology (Chicago, Ill. : 1960)
|April 1, 1980
Summary
This case study presents a patient with advanced olfactory neuroblastoma treated with combination chemotherapy, including dacarbazine, cyclophosphamide, doxorubicin, and vincristine, alongside radiation. The patient achieved a partial response, suggesting chemotherapy
Area of Science:
- Oncology
- Cancer Research
Background:
- Olfactory neuroblastoma is a rare cancer.
- Metastasis at diagnosis, particularly bone marrow involvement, presents a significant challenge.
- Limited data exists on chemotherapy efficacy for advanced olfactory neuroblastoma.
Observation:
- A patient diagnosed with olfactory neuroblastoma presented with bone marrow metastasis.
- Previous treatments included surgery and radiation therapy.
- The patient received a combination chemotherapy regimen: dacarbazine (DTIC-Dome), cyclophosphamide (Cytoxan), doxorubicin hydrochloride (Adriamycin), and vincristine sulfate (Oncovin), along with radiation to the primary tumor site.
Findings:
- Objective evaluation over two years post-diagnosis indicated a good partial response to the combined treatment.
- While reported five-year survival rates are around 50%, the five-year cure rate is notably lower at 18%.
Implications:
- Combination chemotherapy may play a role in managing advanced olfactory neuroblastoma.
- Further investigation into the efficacy of chemotherapy regimens is warranted for specific patient populations.
- This case highlights the need for exploring novel or intensified treatment strategies for metastatic disease.